Add like
Add dislike
Add to saved papers

Photoradiosynthesis of 68Ga-labelled HBED-CC-azepin-MetMAb for immuno-PET of c-MET receptors.

In an alternative approach for radiotracer design, a photoactivatable HBED-CC-PEG3-ArN3 chelate was synthesised and photoconjugated to the anti-c-MET antibody MetMAb (onartuzumab). Photoconjugation gave the functionalised protein HBED-CC-azepin-MetMAb with a photochemical conversion of 18.5±0.5% (n = 2) which was then radiolabelled with 68Ga3+ ions. The purified and formulated [68Ga]GaHBED-CC-azepin-MetMAb radiotracer was evaluated in vitro and in vivo. Standard stability tests and cellular binding assays confirmed that the radiotracer remained radiochemically pure and immunoreactive after photochemical conjugation. [68Ga]GaHBED-CC-azepin-MetMAb showed specific uptake in c-MET-positive MKN-45 (high-expression) and PC-3 (moderate expression) tumours with tumour-associated activities at 6 h post-administration of 10.33±1.27 (n = 5) and 3.88±1.27 (n = 3) %ID/g, respectively. In the competitive blocking experiments, MKN-45 tumour uptake was reduced by approximately 55% (P-value < 0.001 compared with non-blocked experiments) confirming specific radiotracer binding to c-MET in vivo. Radiochemical, cellular and in vivo experiments confirmed that this photoradiochemical approach is a viable tool to synthesise new radiotracers for immuno-PET.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app